Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study.

Trial Profile

Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2015

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Triptocare; Triptocare-LT
  • Sponsors Ipsen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Oct 2013 Planned patient number of the extension trial changed from 315 to 187 according to the ClincalTrials.gov record.
    • 29 Oct 2013 Planned patient number of the extension trial changed from 315 to 187 according to the ClincalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top